Stromedix

edit

Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

Milestones

edit

• 
  Stromedix received $25M in Series B funding. (4/21/08)
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Brad Maroni as Chief Medical Officer.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Shelia Violette as Vice President, Research.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Michael Gilman as Founder and CEO.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Dan Lynch as Executive Chairman.
  Posted 6/3/09 at 10:22pm

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/4/09

Sources

1. Capital Funding Report [edit]